Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established. It claims to be one of the top 30 biopharmas in China, with revenues of $900 million in 2017. Two years ago, when rumors of a Hong Kong IPO first surfaced, it was thought Hansoh’s debut would raise between $1.5 and $3 billion. No estimates for this IPO have are publicly available.
Source: China Biotoday
